 |
| |
Introduction
The Australian antidiabetics market is expected to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now.
Scope
*Forecast for marketed and late-stage pipeline antidiabetic products in Australia
*Assessment of Australia-specific drivers and resistors likely to impact the market
*Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates
*Case study examining the approval and reimbursement process in Australia in general and for several antidiabetics in specific
Highlights
The Australian antidiabetics market is expected to grow from $233m in 2008 to $416m in 2018 at a rate of 6% CAGR. Significant unmet needs in diabetes fuel a large pipeline. The epidemiological growth of the market, impacted by the obesity epidemic and improved diagnosis rates, is further driving the market.
In 2008, the long- and fast-acting insulin classes dominated the insulin market. This situation is not expected to change throughout the forecast period as there is very limited activity within the insulin antidiabetic pipeline and no serious challenges to the market leading therapies.
The strong market position of Avandia in 2007 has all but been destroyed by a meta-analysis published in mid-2007. Despite positive outcomes from GlaxoSmithKline's RECORD trial in 2009, the product will not regain market share before its patent expiry.
Reasons to Purchase
*Identify key opportunities and threats that will impact the use and uptake of new and existing products
*Quantify the future size and scope of the Australian antidiabetics market and predict the performance of key compounds
*Understand critical success factors in growing and defending antidiabetic brand franchises from new entrants and generics
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes: http://www.companiesandmarkets.com/r.ashx?id=B9Y90T6TI188229
|
—
